AU2021312894B2 - Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound - Google Patents

Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Info

Publication number
AU2021312894B2
AU2021312894B2 AU2021312894A AU2021312894A AU2021312894B2 AU 2021312894 B2 AU2021312894 B2 AU 2021312894B2 AU 2021312894 A AU2021312894 A AU 2021312894A AU 2021312894 A AU2021312894 A AU 2021312894A AU 2021312894 B2 AU2021312894 B2 AU 2021312894B2
Authority
AU
Australia
Prior art keywords
day
compound
dose
formula
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021312894A
Other languages
English (en)
Other versions
AU2021312894A1 (en
Inventor
William Brian KIELBASA
Dustin James Mergott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2021312894A1 publication Critical patent/AU2021312894A1/en
Application granted granted Critical
Publication of AU2021312894B2 publication Critical patent/AU2021312894B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2021312894A 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound Active AU2021312894B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055362P 2020-07-23 2020-07-23
US63/055,362 2020-07-23
PCT/US2021/042877 WO2022020663A1 (en) 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Publications (2)

Publication Number Publication Date
AU2021312894A1 AU2021312894A1 (en) 2023-02-23
AU2021312894B2 true AU2021312894B2 (en) 2025-09-11

Family

ID=77338898

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021312894A Active AU2021312894B2 (en) 2020-07-23 2021-07-23 Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound

Country Status (21)

Country Link
US (1) US20230338349A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185291B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023535034A (cg-RX-API-DMAC7.html)
KR (1) KR20230043905A (cg-RX-API-DMAC7.html)
CN (1) CN116323604A (cg-RX-API-DMAC7.html)
AR (1) AR123031A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021312894B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000975A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186808A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000194A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000594A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000009A (cg-RX-API-DMAC7.html)
EC (1) ECSP23005057A (cg-RX-API-DMAC7.html)
ES (1) ES3039536T3 (cg-RX-API-DMAC7.html)
IL (1) IL300023A (cg-RX-API-DMAC7.html)
JO (1) JOP20230018A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000993A (cg-RX-API-DMAC7.html)
PE (1) PE20231031A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550177A1 (cg-RX-API-DMAC7.html)
TW (1) TW202220650A (cg-RX-API-DMAC7.html)
WO (1) WO2022020663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140299A1 (en) * 2017-01-27 2018-08-02 Eli Lilly And Company N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735190B (zh) * 2016-07-22 2019-11-26 深圳市大富科技股份有限公司 Usb金属管件加工设备及其上模板
EP3829634A1 (en) * 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140299A1 (en) * 2017-01-27 2018-08-02 Eli Lilly And Company N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Also Published As

Publication number Publication date
CL2023000194A1 (es) 2023-07-21
EP4185291C0 (en) 2025-07-09
CA3186808A1 (en) 2022-01-27
PE20231031A1 (es) 2023-07-10
IL300023A (en) 2023-03-01
BR112023000975A2 (pt) 2023-02-07
KR20230043905A (ko) 2023-03-31
CN116323604A (zh) 2023-06-23
ES3039536T3 (en) 2025-10-22
ECSP23005057A (es) 2023-02-28
AR123031A1 (es) 2022-10-26
MX2023000993A (es) 2023-03-01
PH12023550177A1 (en) 2024-03-18
AU2021312894A1 (en) 2023-02-23
EP4185291A1 (en) 2023-05-31
US20230338349A1 (en) 2023-10-26
JOP20230018A1 (ar) 2023-01-23
DOP2023000009A (es) 2023-02-15
CO2023000594A2 (es) 2023-01-26
WO2022020663A1 (en) 2022-01-27
EP4185291B1 (en) 2025-07-09
JP2023535034A (ja) 2023-08-15
TW202220650A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
AU2023219839B2 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
AU2016219650B2 (en) Compositions and methods for extended therapy with aminopyridines
WO2003050129A1 (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
JP2022031479A (ja) アルツハイマー病治療に関連するアミロイド関連画像異常の治療または予防方法
TW200815014A (en) Method of improved diuresis in individuals with impaired renal function
AU2018279834A1 (en) Liquid dosage forms to treat cancer
CN111973592A (zh) 治疗肌萎缩侧索硬化和神经病的方法
Browne et al. Bioavailability of ACC‐9653 (phenytoin prodrug)
EP4185291B1 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
Barcia et al. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care
WO2014210369A2 (en) Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
US5712282A (en) Method for therapeutically treating tardive dyskinesia and uses thereof
JP6454436B1 (ja) ペマフィブラートを含有する医薬
US20240245666A1 (en) Dosing regimens
HK40084518A (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
HK40084518B (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
KRESS et al. Pulmonary and meningeal cryptococcosis: Successful treatment of the meningitis with lateral cerebral intraventricular injection of amphotericin B
JP2023049008A (ja) 1回当たりの投与量がイサブコナゾール換算で100~400mgである、イサブコナゾール又はそのプロドラッグを有効成分として含有する製剤
Liau et al. Efficacy and safety of barnidipine compared with felodipine in the treatment of hypertension in Chinese patients
TW200418468A (en) Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
JP2018177773A (ja) 医薬
Brown et al. Phase I trial of sulofenur (LY186641) given orally on a daily× 21 schedule
US20230201107A1 (en) Compositions and methods of administering baclofen
JP5992086B1 (ja) 月経前不快気分障害及び/又は月経前症候群の予防、改善及び治療用医薬組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)